Myolipoma
Myolipoma, also called soft tissue myolipoma (or lipoleiomyoma when it arises in the uterus or internal organs), is an extremely rare benign soft tissue tumor. It is made up of roughly equal proportions of two fully differentiated, benign components intermingled with each other: mature adipocytes and smooth muscle bundles. It contains no malignant elements and no excessive vascular proliferation.
Clinically and pathologically, myolipoma is a soft, slow-growing tumor with a well-defined fibrous capsule. It usually occurs in the retroperitoneum, the deep tissues of the flank and pelvis, the abdominal cavity, or the subcutaneous or intramuscular tissue of adults, most often middle-aged women. Large retroperitoneal lesions can raise suspicion of liposarcoma or leiomyosarcoma, but myolipoma is benign, has no reported metastatic potential and has an excellent outlook once the tumor is completely excised.
At Haute-Derma, we follow a standardized diagnostic pathway: histopathology combined with an immunohistochemistry panel (smooth muscle actin, desmin, S100, MDM2), 3.0T MRI or CT imaging with 3D reconstruction, and microsurgical excision that keeps the tumor capsule intact. This relieves pressure on surrounding structures and gives patients peace of mind.
Clinical Features and Pathological Classification
Pathogenesis and Epidemiology
- Epidemiology: Clearly more common in women (female-to-male ratio about 2:1), with onset typically between ages 40 and 60.
- Locations:
- Deep (deep soft tissue and organs): Retroperitoneum, broad ligament, pelvic and flank region, greater omentum and uterus.
- Superficial / soft tissue: Muscle fascia and subcutaneous tissue of the flank, thigh, neck, shoulder and trunk.
- Biological nature: The tumor reflects biphasic differentiation of benign mesenchymal precursor cells into both fat cells and smooth muscle cells. It is entirely distinct from angiolipoma and myelolipoma.
Histopathology (the Gold Standard)
Under the microscope, myolipoma shows a well-balanced intermixture of two components:
- Mature smooth muscle bundles:
- Fascicles of spindle-shaped smooth muscle cells arranged in parallel or intersecting patterns, with blunt-ended ("cigar-shaped") nuclei and deeply eosinophilic cytoplasm.
- No atypical hyperchromatic nuclei, no abnormal mitotic activity (<1 mitosis per 10 HPF) and no tumor necrosis.
- Mature adipocytes: Lobules of fully mature univacuolar fat cells evenly interspersed between the smooth muscle bundles (fat usually makes up 30%–70% of the tumor volume).
- Other components: A normal network of small blood vessels, without hyaline microthrombi or angioma-like endothelial proliferation.
Differential Diagnosis and Immunohistochemistry (IHC)
The table below summarizes the key features used to rule out malignant retroperitoneal and soft tissue tumors:
| Condition | Immunohistochemical Markers (IHC) | Distinguishing Microscopic Features |
|---|---|---|
| Myolipoma | SMA (+); desmin (+); S100 (+) (in fat); MDM2 (–); CDK4 (–) | Even intermixture of benign smooth muscle bundles and mature fat; no malignant lipoblasts. |
| Well-differentiated liposarcoma (WDLPS / ALT) | Strong MDM2 (+); strong CDK4 (+); MDM2 gene amplification (+) | Atypical lipoblasts with pleomorphic nuclei; atypical fibrous septa; no well-differentiated smooth muscle bundles. |
| Uterine / visceral lipoleiomyoma | SMA (+); desmin (+); ER/PR (+) | Similar to myolipoma but arises from the myometrium; hormone receptors ER/PR (+). |
| Myelolipoma | S100 (+); hematopoietic lineage stains | Mature fat mixed with hematopoietic tissue (erythroid/myeloid elements); no smooth muscle bundles. |
| Angiomyolipoma (AML) | HMB-45 (+); Melan-A (+); SMA (+); S100 (+) | Perivascular epithelioid smooth muscle-like cells (PEComa); thick-walled abnormal vessels; melanocytic marker HMB-45 (+). |
Our Approach to Treating Myolipoma
Haute-Derma manages myolipoma on three principles: confirm the diagnosis by ruling out its mimics, remove the tumor completely with its capsule using microsurgery, and preserve the surrounding anatomy:
- Confirming benign nature with a mandatory IHC panel: We look for the combination of SMA (+), desmin (+), S100 (+) with negative MDM2, CDK4 and HMB-45. A negative MDM2 result reliably excludes liposarcoma, sparing the patient unnecessary organ removal or destructive debulking surgery.
- Complete encapsulated excision: Because myolipoma has a complete fibrous capsule, removing the entire tumor microsurgically is curative.
- 3D imaging localization (MRI/CT): Before surgery, we map exactly how the tumor relates to major blood vessels and the ureter (in retroperitoneal cases) or to the muscle fascia (in soft tissue cases).
How We Diagnose Myolipoma at Haute-Derma
- Clinical examination and history: We assess deep soft tissue masses of the flank, thigh or neck, or examine the abdomen and pelvis in middle-aged women. The mass is usually soft to slightly firm and mobile, and is painless or causes only mild pressure from mechanical compression.
- Advanced imaging (3.0T MRI / multislice CT): The tumor appears well encapsulated, containing fat-density areas (high on T1/T2) interwoven with bands or patches of muscle-like signal (isointense on T1, low to intermediate on T2). MRI clearly defines the boundary between the tumor and neighboring organs.
- Core needle biopsy and IHC: A biopsy sample is stained with H&E (to identify smooth muscle bundles and fat lobules) and with an IHC panel (SMA, desmin, S100, MDM2, HMB-45) to confirm the diagnosis.
Specialized Treatments at Haute-Derma
- Microsurgical excision with intact capsule (enucleation):
- Indication: The gold-standard treatment for myolipoma, both for superficial subcutaneous lesions and for deep lesions within the fascia or abdomen.
- Technique: A small incision hidden in a natural skin crease, followed by careful dissection along the tumor's fibrous capsule to free it from the surrounding muscle, blood vessels and nerves. The wound is closed in several layers with microsurgical sutures to restore a natural contour.
- Decompressive surgery for large retroperitoneal tumors: For large retroperitoneal myolipomas, the surgeon gently separates the tumor from the ureter and iliac vessels without needing to remove the kidney or bowel.
- Scheduled follow-up: Ultrasound or MRI check-ups at 6 months and 1 year. No adjuvant chemotherapy or radiotherapy is needed.
